GQG Partners (ASX: GQG) expects margins to improve in FY24

GQG Partners Inc (ASX: GQG) is an ASX-listed international boutique asset management company which is focused on active equity portfolios. Founded in 2016, the company is headquartered in the US. The company has created a client base with several prominent institutions and crucial wholesale …

Team Kalkine | 26 Feb 2024| Read Time : 10 Mins

Will recent strategic acquisitions help boost Inghams Group’s (ASX: ING) FY24 earnings?

Inghams Group Limited (ASX: ING) is an ASX-listed integrated poultry producing company, engaged in producing and selling turkey and chicken products. In the financial year 2023 (FY23), ING recorded a 12.2% YoY rise in revenue to AUD 3,044 million and 17.9% YoY increase in …

Team Kalkine | 22 Feb 2024| Read Time : 10 Mins

Alkane Resources (ASX: ALK) expects Tomingley to generate gold production of 60-65koz

Alkane Resources Limited (ASX: ALK) is a gold exploration, development, and production company based in Australia. Established in 1969, the company's main projects and operations are situated in central western New South Wales. In the financial year 2023 (FY23), the company recorded more than …

Team Kalkine | 20 Feb 2024| Read Time : 10 Mins

Kalkine: IAG shares set to go ex-dividend tomorrow

>

Team Kalkine | 20 Feb 2024| Read Time : 10 Mins

Kalkine Says: BHP Group Ltd (ASX: BHP) Shares Dip Following Half-Year Results

>

Team Kalkine | 20 Feb 2024| Read Time : 10 Mins

Virgin Money (ASX: VUK) expects further improvement in NIM in FY24

Dual listed company, Virgin Money UK PLC (ASX: VUK) provides banking products and services in the United Kingdom. The AUD 3.94 billion market-cap company made a strong start to the financial year 2024 (FY24) as its first quarter results were in line with guidance. …

Team Kalkine | 19 Feb 2024| Read Time : 10 Mins

Mesoblast (ASX: MSB) focuses on advancing its three lead phase 3 assets

Mesoblast Limited (ASX: MSB) is a biotech company which is focused on developing allogenic cellular medicines for treating severe and life-threatening inflammatory conditions. The company manages a portfolio of late-stage product candidate. In the financial year 2023 (FY23), the company recorded 26.5% YoY decline …

Team Kalkine | 14 Feb 2024| Read Time : 10 Mins